# Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients

> **NCT00402428** · PHASE3 · COMPLETED · sponsor: **Human Genome Sciences Inc.** · enrollment: 1331 (actual)

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** albumin interferon alfa-2b
- **DRUG:** peginterferon alfa-2a
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00402428
- **Lead sponsor:** Human Genome Sciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 1331 (ACTUAL)
- **Last updated:** 2013-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00402428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00402428, "Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared With Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00402428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*